In this TM5614 phase II clinical trial, we investigated whether the PAI‐1 inhibitor combined with TKIs would induce a DMR in patients with CML, using the BCR‐ABL1 transcript as a quantitative marker. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.